Oral isotretinoin therapy for familial Muir-Torre syndrome.
Two representative cases of familial Muir-Torre syndrome are presented. Multiple benign sebaceous neoplasms in both cases and a solitary keratoacanthoma in one were successfully treated with oral isotretinoin. Low-dose maintenance therapy has stabilized the cutaneous manifestations in the two patients, and no new epithelial neoplasms have appeared. This report emphasizes (1) the rationale for the use of isotretinoin in the Muir-Torre syndrome and (2) the potential for a familial pattern of inheritance and a possible association with the cancer family syndrome. It speculates on the prevention of future internal malignancies in Muir-Torre syndrome patients by maintenance oral isotretinoin treatment.
D000284:Administration, Oral; D005260:Female; D006801:Humans; D015474:Isotretinoin; D007636:Keratoacanthoma / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy* / Q000235:genetics; D012626:Sebaceous Gland Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D013577:Syndrome; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use*
D014212:Tretinoin; D015474:Isotretinoin